Brand Engagement Network Inc. a provider of safe and secure generative AI for businesses and their consumers, today announced it has entered into a Vendor Services Project Agreement with a leading global advertising and communications agency, a unit of one of the world’s top advertising holding companies, for the development of a custom AI engagement communication method for a top 10 global pharmaceutical client’s established prescription pharmaceutical drug. The identities of the pharmaceutical company and the agency remain confidential pending a formal release of the AI solution.
Under the agreement, BEN is expected to recognize $250,000 in revenue for development services spanning two Statements of Work in Q4′ 2025. BEN anticipates monthly recurring license fees, separate from the development work, in the first quarter of 2026.
This development, together with BEN’s exclusive Latin American licensing partnership and the new venture to launch Skye Salud an AI healthcare platform for Mexico, is expected to contribute positively to the Company’s Q4 2025 results while highlighting increasing adoption of BEN’s secure AI technology in the healthcare vertical in both the U.S. and Mexico.
Tyler Luck, Acting Chief Executive Officer of BEN, commented, “This agreement reflects BEN’s progression in healthcare, in which our technology delivers trusted, secured, and efficient AI for pharma manufacturers, healthcare providers, and patients. We are committed to creating experiences for consumers where their needs are met with accuracy, reliability, and integrity.”
